TANDEM FARMACEUTICO SL
Company details
- Active NIF/CIF: Not available
-
-
-
-
Address: Paseo Castellana, 123, 28046 Madrid, Madrid, España See in map
-
-
Intracommunity VAT: Not available
Featured products:
More information on TANDEM FARMACEUTICO SL
-
22/09/2008 | BORME act no.: 610453 | Register:Depósito de cuentas anuales (Septiembre de 2008)
-
01/09/2006 | BORME act no.: 300540 | Register: MADRIDDepósito de cuentas anuales (Agosto de 2006)
-
17/10/2003 | BORME act no.: 660344 | Register: MADRIDDepósito de cuentas anuales (octubre de 2003)
-
30/12/2002 | BORME act no.: 524296 | Register: MADRIDConstitución
-
30/12/2002 | BORME act no.: 524296 | Register: MADRIDNombramientos
Other information
The CIF assigned to TANDEM FARMACEUTICO SL is -, and its commercial status is active. The company is engaged in economic activities classified under the CNAE 4774 - Comercio al por menor de artículos médicos y ortopédicos en establecimientos especializados. Additionally, it is categorized with the SIC code 5999 - Detallistas diversos.
TANDEM FARMACEUTICO SL employs approximately Between 10 and 49 employees and records an annual turnover of less than 2 million euros. The company is registered in the Commercial Registry of -, and has 1 registration charges. The most recent announcement in Borme was published on 22/09/2008, while the last deposit of ordinary annual accounts corresponds to the year -.
To find out the contact information of TANDEM FARMACEUTICO SL, such as the telephone number, postal address, or website, you can access the Company Data module.
If you wish to obtain additional information about TANDEM FARMACEUTICO SL, we invite you to consult any of the available financial reports, the Annual Accounts of the company, or review the incidents of defaults registered in the RAI delinquency file.
The financial, commercial, and legal information about TANDEM FARMACEUTICO SL comes from official data sources and is automatically updated every day.
Do you want to know more about TANDEM FARMACEUTICO SL??
Find out more about this company by consulting these reports: